Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma

BackgroundIntrahepatic cholangiocarcinomas (ICC) are relatively rare malignant tumors associated with a poor prognosis. Recent studies using genome-wide sequencing technologies have mainly focused on identifying new driver mutations. There is nevertheless a need to investigate the spectrum of copy number aberrations in order to identify potential target genes in the altered chromosomal regions. The aim of this study was to characterize the patterns of chromosomal copy-number alterations (CNAs) in ICC.Methods53 patients having ICC with frozen material were selected. In 47 cases, DNA hybridization has been performed on a genomewide SNP array. A procedure with a segmentation step and a calling step classified genomic regions into copy-number aberration states. We identified the exclusively amplified and deleted recurrent genomic areas. These areas are those showing the highest estimated propensity level for copy loss (resp. copy gain) together with the lowest level for copy gain (resp. copy loss). We investigated ICC clustering. We analyzed the relationships between CNAs and clinico-pathological characteristics.ResultsThe overall genomic profile of ICC showed many alterations with higher rates for the deletions. Exclusively deleted genomic areas were 1p, 3p and 14q. The main exclusively amplified genomic areas were 1q, 7p, 7q and 8q. Based on the exclusively deleted/amplified genomic areas, a clustering analysis identified three tumors groups: the first group characterized by copy loss of 1p and copy gain of 7p, the second group characterized by 1p and 3p copy losses without 7p copy gain, the last group characterized mainly by very few CNAs. From univariate analyses, the number of tumors, the size of the largest tumor and the stage were significantly associated with shorter time recurrence. We found no relationship between the number of altered cytobands or tumor groups and time to recurrence.ConclusionThis study describes the spectrum of chromosomal aberrations across the whole genome. Some of the recurrent exclusive CNAs harbor candidate target genes. Despite the absence of correlation between CNAs and clinico-pathological characteristics, the co-occurence of 7p gain and 1p loss in a subgroup of patients may suggest a differential activation of EGFR and its downstream pathways, which may have a potential effect on targeted therapies.

[1]  Jesse S. Voss,et al.  Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. , 2012, Human pathology.

[2]  T. Pawlik,et al.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.

[3]  T. Terada,et al.  Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. , 1998, Human pathology.

[4]  P. Dennis,et al.  Akt1 deletion prevents lung tumorigenesis by mutant K-ras , 2011, Oncogene.

[5]  Yuman Fong,et al.  Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract , 2008, Journal of experimental & clinical cancer research : CR.

[6]  Finding exclusively deleted or amplified genomic areas in lung adenocarcinomas using a novel chromosomal pattern analysis , 2009, BMC Medical Genomics.

[7]  Guillem Rigaill,et al.  Pruned dynamic programming for optimal multiple change-point detection , 2010 .

[8]  M. Stucki,et al.  Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition , 2014, Oncotarget.

[9]  Model-Based Clustering using multilocus data with loci selection , 2008 .

[10]  Itzhak Avital,et al.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.

[11]  Y. Totoki,et al.  Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma , 2014, Hepatology.

[12]  W. Palmer,et al.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. , 2012, Journal of hepatology.

[13]  T. Venesio,et al.  Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma , 2006, Clinical Cancer Research.

[14]  S. Fan,et al.  Intrahepatic Cholangiocarcinoma , 1997, World Journal of Surgery.

[15]  A. Tannapfel,et al.  Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver , 2000, Gut.

[16]  N. Hiraoka,et al.  Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma , 2011, British Journal of Cancer.

[17]  G. Gores,et al.  Pathogenesis, diagnosis, and management of cholangiocarcinoma. , 2013, Gastroenterology.

[18]  J. Hartigan,et al.  The Dip Test of Unimodality , 1985 .

[19]  A. Chou,et al.  Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. , 2014, Human pathology.

[20]  L. Wood,et al.  Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups , 2014, Oncotarget.

[21]  Elisabeth Gassiat,et al.  Variable selection in model-based clustering using multilocus genotype data , 2009, Adv. Data Anal. Classif..

[22]  Servane Gey,et al.  Using CART to Detect Multiple Change Points in the Mean for Large Sample , 2008 .

[23]  Guillem Rigaill,et al.  Performance evaluation of DNA copy number segmentation methods , 2014, Briefings Bioinform..

[24]  Bin Tean Teh,et al.  Exome sequencing of liver fluke–associated cholangiocarcinoma , 2012, Nature Genetics.

[25]  G. Gores,et al.  p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. , 2002, Gastroenterology.

[26]  Stephen B. Edge,et al.  Comprar AJCC Cancer Staging Manual + cd-rom 7th Ed | Trotti, Andrea | 9780387884400 | Springer , 2009 .

[27]  C. Pairojkul,et al.  DNA copy-number loss on 1p36.1 harboring RUNX3 with promoter hypermethylation and associated loss of RUNX3 expression in liver fluke-associated intrahepatic cholangiocarcinoma. , 2009, Asian Pacific Journal of Cancer Prevention.

[28]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[29]  Jeffrey W. Clark,et al.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.

[30]  J. Llovet,et al.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies , 2013, Oncogene.

[31]  K. Gunderson,et al.  High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. , 2006, Genome research.

[32]  Tian-Li Wang,et al.  The emerging roles of ARID1A in tumor suppression , 2014, Cancer biology & therapy.

[33]  L. Roberts,et al.  Diagnosis and management of cholangiocarcinoma , 2008, Current gastroenterology reports.

[34]  X. Guan,et al.  Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma , 2010, Acta Pharmacologica Sinica.

[35]  K. Endo,et al.  E‐cadherin gene mutations in human intrahepatic cholangiocarcinoma , 2001, The Journal of pathology.

[36]  A. Torrice,et al.  Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. , 2010, World journal of gastrointestinal oncology.

[37]  Alphonse-E Sirica,et al.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. , 2008, World journal of gastroenterology.

[38]  S. Thorgeirsson,et al.  Genetic profiling of intrahepatic cholangiocarcinoma , 2012, Current opinion in gastroenterology.

[39]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[40]  K. McGlynn,et al.  Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? , 2004, Journal of hepatology.

[41]  Swe Swe Myint,et al.  Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.

[42]  Jesse S. Voss,et al.  Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. , 2013, Human pathology.

[43]  David M. Jones,et al.  New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. , 2014, The oncologist.

[44]  K. Sugimachi,et al.  The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. , 2001, Journal of hepatology.

[45]  A. Ejaz,et al.  Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets , 2014, Annals of Surgical Oncology.

[46]  Eric W. Klee,et al.  Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma , 2014, PLoS genetics.

[47]  H. El‐Serag,et al.  Risk factors for cholangiocarcinoma , 2011, Hepatology.

[48]  Rameen Beroukhim,et al.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. , 2013, Gastroenterology.

[49]  Y. Yen,et al.  Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[50]  W. Schmiegel,et al.  Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. , 1998, Cancer research.

[51]  T. Terada,et al.  Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. , 2002, Journal of hepatology.

[52]  Y. Konishi,et al.  Ki-ras point mutations and proliferation activity in biliary tract carcinomas. , 1996, British Journal of Cancer.